LEVELS OF PROINFLAMMATORY CYTOKINES IL-17 AND IL-23 IN PATIENTS WITH ALZHEIMER’S DISEASE, MILD COGNITIVE IMPAIRMENT AND VASCULAR DEMENTIA

The aim: To research differences of interleukin (IL)-17 and IL-23 serum levels in patients with Alzheimer’s disease, vascular dementia and mild cognitive impairment. Material and methods: Serum levels of IL-17 and IL-23 were measure by ELISA for 15 patients with Alzheimer’s disease, 14 with vascular dementia, 30 with mild cognitive impairment and 30 control individuals without cognitive impairment. Results: Serum concentrations of IL-17 were significantly higher in Alzheimer’s disease patients (P=0.0023) than control, in vascular dementia no significant differences(P=0.4154). Level of IL-23 was significantly higher than control in Alzheimer’s disease patients (P=0.0170) and vascular dementia (P=0.0002), but in Alzheimer’s disease it was in 12.5 time higher. In total mild cognitive impairment patients no significant differences in interleukin concentration with control, but significant differences observed for amnestic form in IL-17 (P=0.0436) and IL-23 (P=0.0019). Conclusions: IL-17 and IL-23 level significant higher in Alzheimer’s disease patients compared with control and vascular dementia. From mild cognitive impairment levels of detectable interleukins was higher in amnestic form that may be early marker of progression in Alzheimer’s disease.

Download Full-text

P2-170: Scope (quantitative) and performance (qualitative) of instrumental ADLs in older adults with mild cognitive impairment: Difference between very mild Alzheimer's disease and very mild subcortical vascular dementia-The Kurihara Project

Alzheimer s & Dementia ◽

10.1016/j.jalz.2012.05.876 ◽

2012 ◽

Vol 8 (4S_Part_9) ◽

pp. P318-P318

Author(s):

Yoshitaka Ouchi ◽

Yuriko Kato ◽

Megumi Nakai ◽

Hiroyasu Ishikawa ◽

Kei Nakamura ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Older Adults ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Vascular Dementia ◽

Subcortical Vascular Dementia ◽

And Performance

Download Full-text

Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment

Scientific Reports ◽

10.1038/s41598-019-56614-5 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 11

Author(s):

Massimiliano Castellazzi ◽

Simone Patergnani ◽

Mariapina Donadio ◽

Carlotta Giorgi ◽

Massimo Bonora ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Late Onset ◽

Memory Loss ◽

Serum Levels ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Samples ◽

Cellular Processes

AbstractDementia is a neurocognitive disorder characterized by a progressive memory loss and impairment in cognitive and functional abilities. Autophagy and mitophagy are two important cellular processes by which the damaged intracellular components are degraded by lysosomes. To investigate the contribution of autophagy and mitophagy in degenerative diseases, we investigated the serum levels of specific autophagic markers (ATG5 protein) and mitophagic markers (Parkin protein) in a population of older patients by enzyme-linked immunosorbent assay. Two hundred elderly (≥65 years) outpatients were included in the study: 40 (20 F and 20 M) with mild-moderate late onset Alzheimer’s disease (AD); 40 (20 F and 20 M) affected by vascular dementia (VAD); 40 with mild cognitive impairment (MCI); 40 (20 F and 20 M) with “mixed” dementia (MD); 40 subjects without signs of cognitive impairment were included as sex-matched controls. Our data indicated that, in serum samples, ATG5 and Parkin were both elevated in controls, and that VAD compared with AD, MCI and MD (all p < 0.01). Patients affected by AD, MD, and MCI showed significantly reduced circulating levels of both ATG5 and Parkin compared to healthy controls and VAD individuals, reflecting a significant down-regulation of autophagy and mitophagy pathways in these groups of patients. The measurement of serum levels of ATG5 and Parkin may represent an easily accessible diagnostic tool for the early monitoring of patients with cognitive decline.

Download Full-text